Michelle Ferreira, MD

Dr. Ferreira seeks to explore dietary, microbial, and metabolic strategies to treat immune-related colitis (ir-colitis), one of the most common autoimmune toxicities resulting from immunotherapy treatment. Ir-colitis results when the patient’s immune system becomes overstimulated after immunotherapy and attacks the colon, leading to diarrhea and other gastrointestinal symptoms that can result in discontinuation of potentially life-saving immunotherapy. Although ir-colitis can be treated with steroids and other immunosuppressive agents, it remains unclear whether this immunosuppression may affect treatment. Targeting the gut microbiome through dietary intervention is a promising strategy to treat ir-colitis without interfering with cancer treatment. She plans to use a mouse model of ir-colitis to study whether intermittent fasting can be used to treat ir-colitis while simultaneously improving tumor control. She will investigate the specific metabolic and gut microbial changes that are responsible for fasting’s effects on ir-colitis, with the goal of expanding non-immunosuppressive and accessible treatment options for this common immunotherapy toxicity.